StockData
Ionis Pharmaceuticals Inc logo

Ionis Pharmaceuticals Inc (IONS) stock

IONSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/303% below fair value
$27.39+0.43 (+1.59%)

Close on Nov 18, 2026Market cap $4.55BP/E –Yield –

Ionis Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Ionis Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$594.36M. For fiscal 2025 it was -$381.68M. The highest annual figure on record is $365.88M in fiscal 2019.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$381.68M–
FY2024Dec 31, 2024-$475.08M–
FY2023Dec 31, 2023-$353.73M–
FY2022Dec 31, 2022-$410.19M–
FY2021Dec 31, 2021-$30.19M–
FY2020Dec 31, 2020-$172.08M-147.0%
FY2019Dec 31, 2019$365.88M–
FY2018Dec 31, 2018-$61.37M-297.7%
FY2017Dec 31, 2017$31.05M–
FY2016Dec 31, 2016-$20.16M–
FY2015Dec 31, 2015-$75.76M–
FY2014Dec 31, 2014-$47.73M–
FY2013Dec 31, 2013-$51.67M–
FY2012Dec 31, 2012-$68.92M–
FY2011Dec 31, 2011-$71.10M–
FY2010Dec 31, 2010-$48.36M–
FY2009Dec 31, 2009-$27.54M–
FY2008Dec 31, 2008-$13.06M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$102.29M-173.2%
Q1 FY2026Mar 31, 2026-$117.42M–
Q4 FY2025Dec 31, 2025-$214.46M–
Q3 FY2025Sep 30, 2025-$160.18M–
Q2 FY2025Jun 30, 2025$139.82M–
Q1 FY2025Mar 31, 2025-$146.86M–
Q4 FY2024Dec 31, 2024-$110.82M–
Q3 FY2024Sep 30, 2024-$148.66M–
Q2 FY2024Jun 30, 2024-$66.09M–
Q1 FY2024Mar 31, 2024-$149.51M–
Q4 FY2023Dec 31, 2023-$6.12M–
Q3 FY2023Sep 30, 2023-$143.27M–
Q2 FY2023Jun 30, 2023-$90.20M–
Q1 FY2023Mar 31, 2023-$114.15M–
Q4 FY2022Dec 31, 2022-$208.02M-194.3%
Q3 FY2022Sep 30, 2022-$59.15M–
Q2 FY2022Jun 30, 2022-$85.51M–
Q1 FY2022Mar 31, 2022-$57.50M–
Q4 FY2021Dec 31, 2021$220.60M–
Q3 FY2021Sep 30, 2021-$85.85M–
Q2 FY2021Jun 30, 2021-$72.97M–
Q1 FY2021Mar 31, 2021-$91.97M–
Q4 FY2020Dec 31, 2020-$22.66M-108.7%
Q3 FY2020Sep 30, 2020-$36.54M-1548.2%
Q2 FY2020Jun 30, 2020-$51.75M–
Q1 FY2020Mar 31, 2020-$61.13M-150.3%
Q4 FY2019Dec 31, 2019$260.65M+2317.5%
Q3 FY2019Sep 30, 2019$2.52M–
Q2 FY2019Jun 30, 2019-$18.83M–
Q1 FY2019Mar 31, 2019$121.54M–
Q4 FY2018Dec 31, 2018$10.78M–
Q3 FY2018Sep 30, 2018-$18.57M-264.2%
Q2 FY2018Jun 30, 2018-$50.28M-879.6%
Q1 FY2018Mar 31, 2018-$3.30M-116.9%
Q4 FY2017Dec 31, 2017-$6.20M-115.1%
Q3 FY2017Sep 30, 2017$11.31M-29.8%
Q2 FY2017Jun 30, 2017$6.45M–
Q1 FY2017Mar 31, 2017$19.49M–
Q4 FY2016Dec 31, 2016$41.16M–
Q3 FY2016Sep 30, 2016$16.11M–

More Ionis Pharmaceuticals figures

See a number that looks wrong?